Guidance On Lab-Developed Tests, Adverse Event Reporting Among US FDA's Priorities For FY 2016
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration's device center has released its annual guidance priority list1, saying it "fully intends" to release final guidance documents on the Medical Device Reporting regulation, Unique Device Identification direct marking, regulatory oversight of laboratory-developed tests and use of ISO 10993-1 biocompatibility standards, among others1.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.